Markers of D2 and D3 receptor activity in vivo: PET scan and prolactin

Therapie

Volumn 63, Issue 3, 2008, Pages 237-242

  Thomasson Perret, Nitza ^a   Pénélaud, Pierre François ^a   Théron, David ^a   Gouttefangeas, Sylvie ^a   Mocaër, Elisabeth ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antipsychotic drug; Dopaminergic system; Extrapyramidal effect; Positrons emisssion tomography; Prolactin

Indexed keywords

AMISULPRIDE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; RACLOPRIDE C 11; RISPERIDONE; S 33138; UNCLASSIFIED DRUG; ZIPRASIDONE; ACETANILIDE DERIVATIVE; BENZOPYRAN DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; N (4 (2 (8 CYANO 1,3A,4,9B TETRAHYDRO(1)BENZOPYRANO(3,4 C)PYRROL 2(3H) YL)ETHYL)PHENYL)ACETAMIDE; N-(4-(2-(8-CYANO-1,3A,4,9B-TETRAHYDRO(1)BENZOPYRANO(3,4-C)PYRROL-2(3H)-YL)ETHYL)PHENYL)ACETAMIDE;

DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; VOLUNTEER; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; METABOLISM; PATHOPHYSIOLOGY;

ACETANILIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZOPYRANS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 54449092425     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2008034     Document Type: Article

References (27)

1. Talbot PS and Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. European Neuro-psychopharmacology 2002; 12: 503-11
2. Farde L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. British Journal of Psychiatry 1992; 160: 30-3
3. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514-20
4. 2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography. Psychopharmacology 1996; 124: 141-7
5. Moore KK. Interactions between prolactin and dopaminergic neurons. Biol Reprod 1987; 36: 47
6. Kane JM, Cooper TB, Sachar EJ, et al. Clozapine: plasma levels and prolactin response. Psychopharmacology 1981; 73: 184-7
7. Hamner MB, Arvantis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636). Psychopharmacol Bull 1996; 32: 107-10
8. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41-54
9. Turrone P, Kapur S, Seeman, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159: 133-5
10. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90
11. 3 receptor antagonists as therapeutic agents. Drug Discov Today 2005; 10(13): 917-25
12. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management. Drug Safety 2005; 28 (3): 191-208
13. 2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology 2004; 175: 473-80
14. Talvik M, Nordstrom AL, Nyberg S, et al. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J psychiatry 2001; 158: 926-30
15. 3 dopamine receptors enhances the antiparkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004; 188: 128-38
16. 3 receptor antagonist. Bioorg Med Chem Lett 1999; 9: 2059-64
17. 2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-Protein-coupled receptors. J of Pharmacol Exp Therapeutics 2008; 324: 587-99
18. 123I]Epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413-20
19. 2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progr Neuro-Psychopharmacol & Biol Psychiatry 2005; 29: 91-6
20. Möller HJ. Risperidone: a review. Expert Opinion Pharmacotherapy 2005; 6(5): 803-18
21. 2 receptor antagonist and potential antipsychotic agent: II. A neurochemical, electrophysiological and behavioural characterization in vivo. J of Pharmacol Exp Therapeutics 2008; 324: 600-11
22. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997; 49: 231-52
23. 3 Dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 2001; 25: 427-43
24. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90: 231-59
25. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6
26. Barnes TRE, Joyce EM. Antipsychotic drug treatment: recent advances. Curr Opin Psychiatr 2001; 14: 25-37
27. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212 (Suppl.): 11-9